Get the Stockscreener App
7.38
6.96%
0.48
Myriad Genetics Inc stock is traded at $7.38, with a volume of 1.45M.
It is up +6.96% in the last 24 hours and down -8.44% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$6.90
Open:
$6.91
24h Volume:
1.45M
Relative Volume:
1.17
Market Cap:
$687.92M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-5.6769
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
+9.99%
1M Performance:
-8.44%
6M Performance:
+81.33%
1Y Performance:
-51.19%
1-Day Range:
$6.82
$7.49
1-Week Range:
$6.43
$7.49
52-Week Range:
$3.76
$16.83
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.38 | 643.17M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
587.48 | 215.18B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
227.39 | 156.94B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
725.91 | 55.05B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
151.25 | 41.12B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
224.90 | 36.97B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Yahoo Finance
Can Myriad Genetics Inc. stock sustain market leadershipMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock nearing a technical breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
Will Myriad Genetics Inc. stock benefit from sector rotationJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
Why analysts upgrade Myriad Genetics Inc. stockJuly 2025 Big Picture & Technical Pattern Recognition Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock a buy on weaknessEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com
Is Myriad Genetics Inc. (MYD) stock attractive for growth fundsMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
How to use a screener to detect Myriad Genetics Inc. breakoutsPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
How Myriad Genetics Inc. (MYD) stock gains from tech spendingQuarterly Investment Review & Weekly Hot Stock Watchlists - newser.com
What’s the recovery path for long term holders of Myriad Genetics Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Will Myriad Genetics Inc. (MYD) stock gain from lower interest ratesBond Market & Real-Time Stock Movement Alerts - newser.com
How Myriad Genetics Inc. (MYD) stock moves in volatile trading sessionsDay Trade & Safe Capital Preservation Plans - newser.com
What earnings revisions data tells us about Myriad Genetics Inc.Market Risk Report & Long-Term Growth Stock Strategies - newser.com
Why Myriad Genetics (MYGN) Stock Is Up Today - Yahoo Finance
Will Myriad Genetics Inc. stock beat EPS estimatesDollar Strength & High Return Trade Opportunity Guides - newser.com
Q3 Earnings Roundup: Myriad Genetics (NASDAQ:MYGN) And The Rest Of The Therapeutics Segment - Barchart.com
What momentum shifts mean for Myriad Genetics Inc.2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
Myriad Genetics at Wolfe Research: Strategic Shift in Cancer Care By Investing.com - Investing.com Canada
(MYGN) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):